S-[4,5-dichloro-2-(1-cyclopropylmethylcyclohexanecarbonylamino)phenyl] 2,2-dimethylthiopropionate | 211513-81-4

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: S-[4,5-dichloro-2-(1-cyclopropylmethylcyclohexanecarbonylamino)phenyl] 2,2-dimethylthiopropionate
• 英文别名: S-[4,5-dichloro-2-[[1-(cyclopropylmethyl)cyclohexanecarbonyl]amino]phenyl] 2,2-dimethylpropanethioate
• CAS: 211513-81-4
• 化学式: C₂₂H₂₉Cl₂NO₂S
• 分子量: 442.45
• InChiKey: MSFCBUDDVRTHPO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.4
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  71.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• CETP activity inhibitors
  申请人：Japan Tobacco Inc.

  公开号：US20040229957A1

  公开（公告）日：2004-11-18

  The present invention provides a CETP activity inhibitor comprising as an active ingredient a compound represented by the formula (I): 1 wherein R represents a straight chain or branched alkyl group; a straight chain or branched alkenyl group; a lower haloalkyl group; a substituted or unsubstituted cycloalkyl group; a substituted or unsubstituted cycloalkenyl group; a substituted or unsubstituted cycloalkylalkyl group; a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group, X 1 , X 2 , X 3 , and X 4 may be the same or different and each represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower haloalkyl group; a lower alkoxy group; a cyano group; a nitro group; an acyl group; or an aryl group, Y represents —CO— or —SO 2 —, and Z represents a hydrogen atom or a mercapto-protecting group, or a prodrug compound, a pharmaceutically acceptable salt, or hydrate or solvate thereof. The compounds represented by the formula (I) can increase HDL and at the same time decrease LDL through selective inhibition of CETP activity and, therefore, is expected to be useful as a new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia.

  本发明提供了一种CETP活性抑制剂，其包括以下式（I）所表示的化合物作为活性成分：其中R表示直链或支链烷基；直链或支链烯基；低卤代烷基；取代或未取代的环烷基；取代或未取代的环烯基；取代或未取代的环烷基烷基；取代或未取代的芳基或取代或未取代的杂环基，X1，X2，X3和X4可以相同也可以不同，每个表示氢原子，卤原子，低烷基，低卤代烷基；低烷氧基；氰基；硝基；酰基；或芳基，Y表示—CO—或—SO2—，Z表示氢原子或硫醇保护基，或其前药化合物，药学上可接受的盐，或其水合物或溶剂化物。公式（I）所表示的化合物可以通过选择性抑制CETP活性来增加HDL并同时降低LDL，因此，预计它将作为一种新型的预防或治疗动脉硬化或高脂血症的药物而有用。
• CETP ACTIVITY INHIBITORS
  申请人：Shinkai Hisashi

  公开号：US20130053417A1

  公开（公告）日：2013-02-28

  The invention provides a compound that is a CETP activity inhibitor. The compound can increase HDL and at the same time decrease LDL through selective inhibition of CETP activity, the invention also provides for the use of the compound to prevent or treat atherosclerosis or hyperlipidemia.

  本发明提供了一种CETP活性抑制剂的化合物。该化合物可以通过选择性抑制CETP活性来增加HDL并同时降低LDL，本发明还提供了使用该化合物预防或治疗动脉粥样硬化或高脂血症的方法。
• CETP activity inhibitor
  申请人：Japan Tobacco, Inc., a Japan Corporation

  公开号：US20030092708A1

  公开（公告）日：2003-05-15

  The present invention provides a CETP activity inhibitor comprising as an active ingredient a compound represented by the formula (I): 1 wherein R represents a straight chain or branched alkyl group; a straight chain or branched alkenyl group; a lower haloalkyl group; a substituted or unsubstituted cycloalkyl group; a substituted or unsubstituted cycloalkenyl group; a substituted or unsubstituted cycloalkylalkyl group; a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group, X 1 , X 2 , X 3 , and X 4 may be the same or different and each represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower haloalkyl group; a lower alkoxy group; a cyano group; a nitro group; an acyl group; or an aryl group, Y represents —CO— or —SO 2 —, and Z represents a hydrogen atom or a mercapto-protecting group, or a prodrug compound, a pharmaceutically acceptable salt, or hydrate or solvate thereof. The compounds represented by the formula (I) can increase HDL and at the same time decrease LDL through selective inhibition of CETP activity and, therefore, is expected to be useful as a new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia.

  本发明提供了一种CETP活性抑制剂，其作为活性成分包含由式（I）表示的化合物：1其中R表示直链或支链烷基；直链或支链烯基；低卤代烷基；取代或未取代的环烷基；取代或未取代的环烯基；取代或未取代的环烷基烷基；取代或未取代的芳基或取代或未取代的杂环基，X1、X2、X3和X4可以相同也可以不同，每个表示氢原子、卤原子、低烷基、低卤代烷基、低烷氧基、氰基、硝基、酰基或芳基，Y表示—CO—或—SO2—，Z表示氢原子或巯基保护基，或其前药化合物、药学上可接受的盐、水合物或溶剂化物。由式（I）表示的化合物可以通过选择性抑制CETP活性来增加HDL并同时降低LDL，因此预计可用作新型的动脉粥样硬化或高脂血症的预防或治疗剂。
• CETP Activity Inhibitors
  申请人：Shinkai Hisashi

  公开号：US20080027109A1

  公开（公告）日：2008-01-31

  The present invention provides a CETP activity inhibitor comprising as an active ingredient a compound represented by the formula (I): wherein R represents a straight chain or branched alkyl group; a straight chain or branched alkenyl group; a lower haloalkyl group; a substituted or unsubstituted cycloalkyl group; a substituted or unsubstituted cycloalkenyl group; a substituted or unsubstituted cycloalkylalkyl group; a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group, X 1 , X 2 , X 3 , and X 4 may be the same or different and each represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower haloalkyl group; a lower alkoxy group; a cyano group; a nitro group; an acyl group; or an aryl group, Y represents —CO— or —SO 2 —, and Z represents a hydrogen atom or a mercapto-protecting group, or a prodrug compound, a pharmaceutically acceptable salt, or hydrate or solvate thereof. The compounds represented by the formula (I) can increase HDL and at the same time decrease LDL through selective inhibition of CETP activity and, therefore, is expected to be useful as a new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia.

  本发明提供了一种CETP活性抑制剂，其包含以下式子（I）表示的化合物作为活性成分：其中R表示直链或支链烷基；直链或支链烯基；低卤代烷基；取代或未取代环烷基；取代或未取代环烯基；取代或未取代环烷基烷基；取代或未取代芳基；或取代或未取代杂环基，X1、X2、X3和X4可以相同或不同，每个表示氢原子、卤素原子、低烷基、低卤代烷基；低烷氧基；氰基；硝基；酰基；或芳基，Y表示—CO—或—SO2—，Z表示氢原子或巯基保护基，或其前药化合物，药学上可接受的盐或其水合物或溶剂化物。式（I）所表示的化合物可以通过选择性抑制CETP活性增加HDL并同时降低LDL，因此预计可作为一种新型的预防或治疗动脉粥样硬化或高脂血症的药物。
• Pharmaceutical compositions of CETP inhibitors
  申请人：Japan Tobacco, Inc.

  公开号：EP2289507A1

  公开（公告）日：2011-03-02

  The invention provides pharmaceutical compositions comprising a cholesteryl ester transfer protein (CEPT) inhibitor and a water-insoluble concentration-enhancing additive, which exhibit improved bioavailability. The invention also provides methods of treating cardiovascular disorders comprising the administration of the pharmaceutical compositions comprising a CETP inhibitor.

  本发明提供了由胆固醇酯转移蛋白（CEPT）抑制剂和水不溶性浓度增强添加剂组成的药物组合物，其生物利用度有所提高。本发明还提供了治疗心血管疾病的方法，包括服用包含 CETP 抑制剂的药物组合物。